title: Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma.
abstract: BACKGROUND
  Synchronous bilateral breast carcinoma (SBBC) is an uncommon presentation, and the management of patients with this disease is not well established.
  
  
  METHODS
  In order to evaluate whether patients with early-stage SBBC could be safely and effectively treated with bilateral breast-conserving therapy (BCT), the authors retrospectively reviewed the records of 24 patients with clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month apart. The median age at diagnosis was 56 years (range, 32-85 years), and the median follow-up for surviving patients was 95 months (range, 68-157 months). Pathology slides were available for review in 19 cases. Cosmetic results and complications after BCT were scored. Outcome was compared with that of 1314 patients with unilateral Stage I or II breast carcinoma, within the same age range, treated during the same time period.
  
  
  RESULTS
  There were no significant differences between the SBBC and unilateral groups in actuarial disease free survival (70% and 74%, respectively, at 5 years), overall survival (88% and 87%, respectively, at 5 years), or crude distribution of sites of first failure. Multivariate analysis of overall survival and disease free survival also did not show bilaterality to be a significant factor. The cosmetic results for the SBBC group were not significantly different from those for the unilateral group. Physician assessment of cosmetic outcome was excellent in 57% and good in 43% of SBBC patients evaluated 25-48 months after BCT. Long term complications were rare in both groups.
  
  
  CONCLUSIONS
  Patients with early-stage SBBC can be safely treated with carefully planned, bilateral BCT, with outcome that appears to be comparable to that of patients with early-stage unilateral breast carcinoma.
authors.affiliation: Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: S V
authors.initials: SV
authors.lastname: Gollamudi
authors.forename: R S
authors.initials: RS
authors.lastname: Gelman
authors.forename: G
authors.initials: G
authors.lastname: Peiro
authors.forename: L J
authors.initials: LJ
authors.lastname: Schneider
authors.forename: S J
authors.initials: SJ
authors.lastname: Schnitt
authors.forename: A
authors.initials: A
authors.lastname: Recht
authors.forename: B J
authors.initials: BJ
authors.lastname: Silver
authors.forename: J R
authors.initials: JR
authors.lastname: Harris
authors.forename: J L
authors.initials: JL
authors.lastname: Connolly
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery*; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary; D012189:Retrospective Studies; D016896:Treatment Outcome